Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM)
暂无分享,去创建一个
T. Tashi | C. Ustun | V. Pullarkat | P. Bose | J. Sachs | M. Piris-Villaespesa | H. Jolin | Daniel J. DeAngelo | M. Heaney | B. Exter | Jay L. Patel | Lei Sun | T. George | A. Pilla